Bharat Biotech's Covaxin ready for phase 3 trials after no adverse effects in 2 trials
Image Credit: Shortpedia
Bharat Biotech said that its coronavirus vaccine candidate COVAXIN has shown no adverse effects in the first two stages of trials. The vaccine has received approval to conduct Phase III human trials and it aims to attain a strong immune response rate in clinical trials. Over 1,000 people took part in the two trials of India's first indigenous coronavirus vaccine. Bharat Biotech has tested four different strains in India.